Literature DB >> 28511343

Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors.

Fatemeh Tavanafar1, Reza Safaralizadeh2, Mohammad Ali Hosseinpour-Feizi2, Behzad Mansoori1, Dariush Shanehbandi1, Ali Mohammadi1, Behzad Baradaran3.   

Abstract

INTRODUCTION: Breast adenocarcinoma is the second common cancer in women the incidence of which is increasing in many countries, especially in developing companies. In this study, miRNA143 has been replaced by vector based microRNA-143 in breast adenocarcinoma cells (MDA-MB-468) and its anti-cancer effects on breast adenocarcinoma cells have been evaluated.
METHODS: The pCMV-MIR-143 vector was transfected into MDA-MB-468 cells via JetPEI transfection reagent. The transfected cells were selected by IC50 concentration of Geneticin antibiotic (G418) after a 2-week treatment. To evaluate the effect of miR-143 on the inhibition of migration, scratch wound healing assay was performed. Then, the expression level of miR-143, Kras, Vimentin, CXCR4, MMP9 and E-Cadherin were measured by the qRT-PCR method.
RESULTS: Results of MTT and wound healing assays showed that miR-143 inhibited cell growth and cell migration in miR-143 induced cell line compared with control group. The result of gene expression showed that miR-143 reduced Kras, Vimentin, CXCR4 and MMP9 expression, and increased E-Cadherin expression in miR-143 replaced cells compared to control cells.
CONCLUSION: The results showed that miRNA-143 plays an important role in cell growth and migration during breast cancer development and metastasis and it can be a candidate as a therapeutic molecule in microRNA replacement therapy of breast adenocarcinoma.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Breast adenocarcinoma; Metastasis; Therapy; miR-143; microRNA replacement

Mesh:

Substances:

Year:  2017        PMID: 28511343     DOI: 10.1016/j.biopha.2017.04.119

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  Long non-coding RNA HOTAIR promotes cervical cancer progression through regulating BCL2 via targeting miR-143-3p.

Authors:  Mingzhu Liu; Jinying Jia; Xinjie Wang; Yanjie Liu; Chunfang Wang; Ruitai Fan
Journal:  Cancer Biol Ther       Date:  2018-02-06       Impact factor: 4.742

Review 2.  MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.

Authors:  Adriana Fodor; Andrada Luciana Lazar; Cristina Buchman; Brandusa Tiperciuc; Olga Hilda Orasan; Angela Cozma
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

3.  Aberrant Expression of miR-103, miR-184, miR-378, miR-497 and miR-506 in Tumor Tissue from Patients with Oral Squamous Cell Carcinoma Regulates the Clinical Picture of the Patients.

Authors:  Maryam Ghffari; Milad Asadi; Dariush Shanaehbandi; Soghra Bornehdeli; Mahsa Sadeghzadeh; Haniye Mohammad Reza Khani; Shahram Ghasembaglou
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

4.  Human Mesenchymal Stem Cell-Derived Exosomal microRNA-143 Promotes Apoptosis and Suppresses Cell Growth in Pancreatic Cancer via Target Gene Regulation.

Authors:  Bingyi Wang; Yan Xu; Yuhua Wei; Lixin Lv; Nanbin Liu; Rui Lin; Xiuyan Wang; Baomin Shi
Journal:  Front Genet       Date:  2021-02-12       Impact factor: 4.599

5.  Restoration of miRNA-143 Expression Inhibits Growth and Migration of MKN-45 Gastric Cancer Cell Line.

Authors:  Nayer Hosseinahli; Tahereh Zeinali; Nasrin Hosseinahli; Leila Karimi; Dariush Shanehbandi; Behzad Mansoori; Ali Mohammadi; Tohid Kazemi; Khalil Hajiasgharzadeh; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2020-10-20

6.  Screening of miRNAs in White Blood Cell as a Radiation Biomarkers for Rapid Assessment of Acute Radiation Injury.

Authors:  Jiaxun Li; Zhefan Shen; Wei Chen; Zhenlan Feng; Lan Fang; Jianpeng Zhao; Cong Liu; Jicong Du; Ying Cheng
Journal:  Dose Response       Date:  2022-09-16       Impact factor: 2.623

7.  MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy.

Authors:  Yalda Baghay Esfandyari; Mohammad Amin Doustvandi; Mohammad Amini; Behzad Baradaran; Sheyda Jodeiry Zaer; Nazila Mozammel; Mehdi Mohammadzadeh; Ahad Mokhtarzadeh
Journal:  Reprod Sci       Date:  2021-02-10       Impact factor: 3.060

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.